Skip to main content

Table 3 Clinical and economic outcomes for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence (discounted by 3%)

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

OutcomesCAZ-AVI sequenceaCeftolozane/Tazobactam sequenceb
% of patients with cure93.04%91.52%
% of patients died in hospital5.02%5.60%
% of patients with AE6.12%7.48%
Average number of days in hospital13.0413.42
LYs4.4114.384
QALYs4.0213.982
Drug costs€ 2952€ 2324
Hospitalisation costs€ 11,355€ 11,781
SAE costs€ 185€ 226
Recurrence costs€ 0€ 0
Total costs€ 14,492€ 14,331
Incremental cost per QALY gained€ 4099
  1. AE = adverse event; CAZ-AVI = ceftazidime-avibactam; LY = life year; QALY = quality-adjusted life year; SAE = serious adverse event.
  2. aCAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem
  3. bCeftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem